Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Avadel Pharmaceuticals Plc (AVDL)

Avadel Pharmaceuticals Plc (AVDL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 434,911
  • Shares Outstanding, K 58,221
  • Annual Sales, $ 59,220 K
  • Annual Income, $ -33,230 K
  • 60-Month Beta 1.37
  • Price/Sales 7.19
  • Price/Cash Flow N/A
  • Price/Book 2.49
Trade AVDL with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.28
  • Number of Estimates 7
  • High Estimate -0.11
  • Low Estimate -0.44
  • Prior Year -0.07
  • Growth Rate Est. (year over year) -300.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.95 +50.91%
on 10/30/20
7.55 -1.06%
on 11/27/20
+2.11 (+39.37%)
since 10/27/20
3-Month
4.83 +54.66%
on 09/24/20
7.55 -1.06%
on 11/27/20
+1.12 (+17.64%)
since 08/27/20
52-Week
4.00 +86.75%
on 03/18/20
13.49 -44.63%
on 04/27/20
+1.26 (+20.29%)
since 11/27/19

Most Recent Stories

More News
Avadel Pharmaceuticals to Present at Upcoming December 2020 Investor Conferences

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy...

AVDL : 7.47 (+2.19%)
Avadel Pharmaceuticals to Present at Upcoming November 2020 Investor Conferences

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy...

AVDL : 7.47 (+2.19%)
Avadel: 3Q Earnings Snapshot

DUBLIN (AP) _ Avadel Pharmaceuticals PLC (AVDL) on Monday reported a loss of $11.7 million in its third quarter.

AVDL : 7.47 (+2.19%)
Avadel Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Update on FT218 Development Program

-- NDA for once-nightly FT218 is on track for FDA submission by end of December 2020

AVDL : 7.47 (+2.19%)
Avadel Pharmaceuticals Plc to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 9, 2020 / Avadel Pharmaceuticals Plc (NASDAQ:AVDL) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on November 9, 2020...

AVDL : 7.47 (+2.19%)
Avadel Pharmaceuticals to Report Third Quarter 2020 Financial Results on November 9th

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy...

AVDL : 7.47 (+2.19%)
Thinking about buying stock in Avadel Pharmaceuticals, Nikola Corp, Agile Therapeutics, Biocept Inc, or Uber Technologies?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVDL, NKLA, AGRX, BIOC, and UBER.

AVDL : 7.47 (+2.19%)
BIOC : 4.44 (-1.11%)
UBER : 50.72 (-0.16%)
Avadel to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Avadel Pharmaceuticals plc (Nasdaq: AVDL) a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate, today announced that its executive team will be presenting...

MHMNF : 54.5000 (unch)
AVDL : 7.47 (+2.19%)
Avadel Pharmaceuticals Announces FT218 Leadership Transition

-- Seasoned industry veteran and Avadel Board member, Mark McCamish, M.D., Ph.D., to work with management and provide direct leadership of the FT218 program

AVDL : 7.47 (+2.19%)
Avadel to Present at H.C. Wainwright 22nd Annual Global Investment Conference

Avadel Pharmaceuticals plc (Nasdaq: AVDL) a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate, today announced that its executive team will be presenting...

AVDL : 7.47 (+2.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Avadel Pharmaceuticals plc is a specialty pharmaceutical company. Its product pipeline consists of hospital and paediatrics. Hospital segment provides Bloxiverz(R), Vazculep(R) and Akovaz(TM). Paediatrics segment provides Karbinal (TM) ER, AcipHex(R) Sprinkle and Flexichamber(TM). The company operates...

See More

Key Turning Points

2nd Resistance Point 7.69
1st Resistance Point 7.58
Last Price 7.47
1st Support Level 7.33
2nd Support Level 7.19

See More

52-Week High 13.49
Fibonacci 61.8% 9.86
Fibonacci 50% 8.74
Fibonacci 38.2% 7.63
Last Price 7.47
52-Week Low 4.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar